Sagimet Biosciences Inc（SGMT）の財務SGMTSagimet Biosciences Inc

Evaluating the bottom line, Sagimet Biosciences Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -24.37%, provide a clear picture of how effectively SGMT converts its operational activities into shareholder value.

In the context of the broader market, SGMT competes directly with industry leaders such as IMMX and ACHV. With a market capitalization of $679.30M, it holds a significant position in the sector. When comparing efficiency, SGMT's gross margin of N/A stands against IMMX's N/A and ACHV's N/A. Such benchmarking helps identify whether Sagimet Biosciences Inc. is trading at a premium or discount relative to its financial performance.

Sagimet's financial performance shows consistent net losses, with the latest EPS reported at -0.26 for Q2 2026. However, the company's current ratio is exceptionally high at 45.02, indicating strong liquidity to cover short-term liabilities.